DiaMedica Therapeutics (DMAC) Cash & Equivalents (2017 - 2026)

DiaMedica Therapeutics has reported Cash & Equivalents for 10 years, with the latest figure at $4.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 88.03% year-over-year to $4.9 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 88.03% YoY), and the FY2025 full-year result was $15.6 million, up 417.26% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.9 million, down from $15.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $15.6 million in Q4 2025, with the low at $2.1 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $4.8 million across 5 years, with a median of $3.3 million in 2025.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 82.92% — and 2025, when it jumped 417.26%.
• DiaMedica Therapeutics' Cash & Equivalents stood at $4.7 million in 2022, then fell by 3.91% to $4.5 million in 2023, then slumped by 33.41% to $3.0 million in 2024, then jumped by 417.26% to $15.6 million in 2025, then slumped by 68.89% to $4.9 million in 2026.
• The last three Cash & Equivalents figures came in at $4.9 million (Q1 2026), $15.6 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.